The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Prognostic impact of tumor-associated macrophage infiltration in non-small cell lung cancer: A systemic review and meta-analysis
Open accessAbstract
// Jiandong Mei 1, 2, * , Zhilan Xiao 1, 2, * , Chenglin Guo 1, 2 , Qiang Pu 1, 2 , Lin Ma 1, 2 , Chengwu Liu 1, 2 , Feng Lin 1, 2 , Hu Liao 1, 2 , Zongbing You 3 , Lunxu Liu 1, 2 1 Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China 2 Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, China 3 Department of Structural and Cellular Biology, Tulane University, New Orleans, LA 70112, USA * These authors contributed equally to this work Correspondence to: Lunxu Liu, email: lunxu_liu@aliyun.com Zongbing You, email: zyou@tulane.edu Keywords: clinicopathological characteristics, non-small cell lung cancer (NSCLC), prognosis, tumor-associated macrophages (TAMs) Received: February 24, 2016 Accepted: April 11, 2016 Published: April 28, 2016 ABSTRACT Tumor-associated macrophages (TAMs) are important components of cancer microenvironment. In the present study, we searched PubMed, Embase, Cochrane library and Web of Science to perform a meta-analysis of 20 studies including a total of 2,572 non-small cell lung cancer (NSCLC) patients, in order to determine the association between TAMs and NSCLC prognosis. The combined hazard ratio (HR) of 9 studies showed that the density of total CD68 + TAMs in the tumor islet and stroma was not associated with overall survival (OS) of the patients. However, the pooled HR of 4 studies showed that high density of CD68 + TAMs in the tumor islet predicted better OS, while the pooled HR of 6 studies showed that high density of CD68 + TAMs in the tumor stroma was associated with poor OS. A high islet/stroma ratio of CD68 + TAMs was associated with better OS. A high density of M1 TAMs in the tumor islet was associated with better OS, while a high density of M2 TAMs in the tumor stroma predicted poor OS. These findings suggest that, although the density of total CD68 + TAMs is not associated with OS, the localization and M1/M2 polarization of TAMs are potential prognostic predictors of NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
Macrophage polarization in tumour progression
Sica, A., Larghi, P., Mancino, A., Rubino, L., Porta, C., Totaro, M. G., Rimoldi, M., Biswas, S. K., Allavena, P., & Mantovani, A. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.03.004 · Cited by 1,241
Cited by
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 840
Influence of Resveratrol on the Immune Response
Malaguarnera, L. (2019) · Nutrients · doi:10.3390/nu11050946 · Cited by 526
The roles of tumor-associated macrophages in tumor angiogenesis and metastasis
Fu, L.-Q., Du, W.-L., Cai, M.-H., Yao, J.-Y., Zhao, Y.-Y., & Mou, X.-Z. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104119 · Cited by 415
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
Guan, F., Wang, R., Yi, Z., Luo, P., Liu, W., Xie, Y., Liu, Z., Xia, Z., Zhang, H., & Cheng, Q. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02124-y · Cited by 371
Xu, F., Cui, W.-Q., Wei, Y., Cui, J., Qiu, J., Hu, L.-L., Gong, W.-Y., Dong, J.-C., & Liu, B.-J. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0878-0 · Cited by 331
Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies
Kumari, N., & Choi, S. H. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02272-x · Cited by 315
Emerging role of tumor cell plasticity in modifying therapeutic response
Qin, S., Jiang, J., Lu, Y., Nice, E. C., Huang, C., Zhang, J., & He, W. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00313-5 · Cited by 268
Parayath, N. N., Parikh, A., & Amiji, M. M. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b00689 · Cited by 262
Cassetta, L., & Kitamura, T. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00038 · Cited by 200
“…in different cancers, and indicated that high infiltration of TAM correlates with poor overall survival in breast, gastric, oral, ovarian, bladder and thyroid cancers, but not in colorectal cancer (Zhang et al., 2012; Guo et al., 2016; Mei et al., 2016; Yin et al., 2017; Zhao et al., 2017).”
BackgroundThe M1/M2 spectrum and plasticity of malignant pleural effusion-macrophage in advanced lung cancer
Wu, M.-F., Lin, C.-A., Yuan, T.-H., Yeh, H.-Y., Su, S.-F., Guo, C.-L., Chang, G.-C., Li, K.-C., Ho, C.-C., & Chen, H.-W. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02781-8 · Cited by 48
Self-citationLu, J., Duan, Y., Liu, P., He, X., Yang, Y., Zhang, R., & Weng, L. (2023) · The Journal of Pathology · doi:10.1002/path.6015 · Cited by 6
Metadata
- Authors
- Mei, J., Xiao, Z., Guo, C., Pu, Q., Ma, L., Liu, C., Lin, F., Liao, H., You, Z., & Liu, L.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-04-28
- Volume
- 7
- Issue
- 23
- Pages
- 34217-34228
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2343682798
- Cited by
- 196
- References
- 4
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.